{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:10:20Z","timestamp":1789704620726,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Jiangsu Provincial Key Research and Development Plan","award":["No. BE2018659"],"award-info":[{"award-number":["No. BE2018659"]}]},{"name":"Provincial Key Laboratory Program of Higher\u2002Education","award":["No. KJS1867"],"award-info":[{"award-number":["No. KJS1867"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10388-020-00753-6","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T02:02:31Z","timestamp":1591754551000},"page":"144-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis"],"prefix":"10.1007","volume":"18","author":[{"given":"Liting","family":"Xi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhou","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merlin","family":"Muktiali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3576-3879","authenticated-orcid":false,"given":"Airong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"753_CR1","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil","year":"2006","unstructured":"Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900\u201320 (quiz 1943).","journal-title":"Am J Gastroenterol"},{"key":"753_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","volume":"63","author":"HB El-Serag","year":"2014","unstructured":"El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871\u201380.","journal-title":"Gut"},{"key":"753_CR3","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1136\/gutjnl-2017-314722","volume":"67","author":"CP Gyawali","year":"2018","unstructured":"Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67:1351\u201362.","journal-title":"Gut"},{"key":"753_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2017.07.045","volume":"154","author":"JE Richter","year":"2018","unstructured":"Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology. 2018;154:267\u201376.","journal-title":"Gastroenterology"},{"key":"753_CR5","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1136\/gutjnl-2016-311715","volume":"65","author":"KM Fock","year":"2016","unstructured":"Fock KM, Talley N, Goh KL, et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. Gut. 2016;65:1402\u201315.","journal-title":"Gut"},{"key":"753_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/nyas.13845","volume":"1434","author":"CP Gyawali","year":"2018","unstructured":"Gyawali CP, Azagury DE, Chan WW, et al. Nonerosive reflux disease: clinical concepts. Ann NY Acad Sci. 2018;1434:290\u2013303.","journal-title":"Ann NY Acad Sci"},{"key":"753_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","volume":"51","author":"K Iwakiri","year":"2016","unstructured":"Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751\u201367.","journal-title":"J Gastroenterol"},{"key":"753_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.gastro.2017.07.049","volume":"154","author":"CP Gyawali","year":"2018","unstructured":"Gyawali CP, Fass R. Management of gastroesophageal reflux disease. Gastroenterology. 2018;154:302\u201318.","journal-title":"Gastroenterology"},{"key":"753_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.tips.2011.02.007","volume":"32","author":"T Hershcovici","year":"2011","unstructured":"Hershcovici T, Fass R. Pharmacological management of GERD: where does it stand now? Trends Pharmacol Sci. 2011;32:258\u201364.","journal-title":"Trends Pharmacol Sci"},{"key":"753_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","volume":"22","author":"R Fass","year":"2005","unstructured":"Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease\u2013where next? Aliment Pharmacol Ther. 2005;22:79\u201394.","journal-title":"Aliment Pharmacol Ther"},{"key":"753_CR11","doi-asserted-by":"publisher","first-page":"117955221770945","DOI":"10.1177\/1179552217709456","volume":"10","author":"KY Marakhouski","year":"2017","unstructured":"Marakhouski KY, Karaseva GA, Ulasivich DN, et al. Omeprazole-domperidone fixed dose combination vs omeprazole monotherapy: a phase 4, open-label, comparative, parallel randomized controlled study in mild to moderate gastroesophageal reflux disease. Clin Med Insights Gastroenterol. 2017;10:1179552217709456.","journal-title":"Clin Med Insights Gastroenterol"},{"key":"753_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/gut.50.1.19","volume":"50","author":"Q Zhang","year":"2002","unstructured":"Zhang Q, Lehmann A, Rigda R, et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut. 2002;50:19\u201324.","journal-title":"Gut"},{"key":"753_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10620-018-5377-9","volume":"64","author":"H Yamashita","year":"2019","unstructured":"Yamashita H, Okada A, Naora K, et al. Adding acotiamide to gastric acid inhibitors is effective for treating refractory symptoms in patients with non-erosive reflux disease. Dig Dis Sci. 2019;64:823\u201331.","journal-title":"Dig Dis Sci"},{"key":"753_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.5056\/jnm16100","volume":"23","author":"JY Lee","year":"2017","unstructured":"Lee JY, Kim SK, Cho KB, et al. A double-blind, randomized, multicenter clinical trial investigating the efficacy and safety of esomeprazole single therapy versus mosapride and esomeprazole combined therapy in patients with esophageal reflux disease. J Neurogastroenterol Motility. 2017;23:218\u201328.","journal-title":"J Neurogastroenterol Motility"},{"key":"753_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1442-2050.2004.00424.x","volume":"17","author":"K Madan","year":"2004","unstructured":"Madan K, Ahuja V, Kashyap PC, et al. Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. Dis Esophagus. 2004;17:274\u20138.","journal-title":"Dis Esophagus"},{"key":"753_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/00042737-200108000-00006","volume":"13","author":"CJ van Rensburg","year":"2001","unstructured":"van Rensburg CJ, Bardhan KD. No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2001;13:909\u201314.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"753_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/j.1365-2036.1995.tb00382.x","volume":"9","author":"JM Kimmig","year":"1995","unstructured":"Kimmig JM. Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies. Aliment Pharmacol Ther. 1995;9:281\u20136.","journal-title":"Aliment Pharmacol Ther"},{"key":"753_CR18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/jgh.13970","volume":"33","author":"T Takeuchi","year":"2018","unstructured":"Takeuchi T, Takahashi Y, Kawaguchi S, et al. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. J Gastroenterol Hepatol. 2018;33:623\u201330.","journal-title":"J Gastroenterol Hepatol"},{"key":"753_CR19","first-page":"A22","volume":"4","author":"H Yamashita","year":"2016","unstructured":"Yamashita H, Kanamori A, Okada A. Efficacy of acotiamide in patients with gastroesophageal reflux disease unresponsive to proton pump inhibitor therapy. United Eur Gastroenterol J. 2016;4:A22\u2013A23.","journal-title":"United Eur Gastroenterol J"},{"key":"753_CR20","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.11569\/wcjd.v22.i36.5671","volume":"22","author":"YP Wang","year":"2014","unstructured":"Wang YP, Ji LS, Ni M, et al. Clinical effects of esomeprazole combined with mosapride for treatment of gastroesophageal reflux disease. World Chin J Digestol. 2014;22:5671\u20134.","journal-title":"World Chin J Digestol"},{"key":"753_CR21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s10620-012-2430-y","volume":"58","author":"YK Cho","year":"2013","unstructured":"Cho YK, Choi MG, Park EY, et al. Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry. Dig Dis Sci. 2013;58:1035\u201341.","journal-title":"Dig Dis Sci"},{"key":"753_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2036.2010.04517.x","volume":"33","author":"H Miwa","year":"2011","unstructured":"Miwa H, Inoue K, Ashida K, et al. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33:323\u201332.","journal-title":"Aliment Pharmacol Ther"},{"key":"753_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/1751-2980.12167","volume":"15","author":"Y Yamaji","year":"2014","unstructured":"Yamaji Y, Isomura Y, Yoshida S, et al. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease. J Digest Dis. 2014;15:469\u201376.","journal-title":"J Digest Dis"},{"key":"753_CR24","first-page":"1221","volume":"13","author":"M Abbasinazari","year":"2014","unstructured":"Abbasinazari M, Panahi Y, Mortazavi SA, et al. Effect of a combination of omeprazole plus sustained release baclofen versus omeprazole alone on symptoms of patients with Gastroesophageal Reflux Disease (GERD). Iran J Pharmaceutical Res. 2014;13:1221\u20136.","journal-title":"Iran J Pharmaceutical Res"},{"key":"753_CR25","first-page":"233","volume":"43","author":"S Ndraha","year":"2011","unstructured":"Ndraha S. Combination of PPI with a prokinetic drug in gastroesophageal reflux disease. Acta medica indonesiana. 2011;43:233\u20136.","journal-title":"Acta medica indonesiana"},{"key":"753_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2125.2010.03696.x","volume":"70","author":"YC Hsu","year":"2010","unstructured":"Hsu YC, Yang TH, Hsu WL, et al. Mosapride as an adjunct to lansoprazole for symptom relief of reflux oesophagitis. Br J Clin Pharmacol. 2010;70:171\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"753_CR27","first-page":"117955221770945","volume":"10","author":"KY Marakhouski","year":"2017","unstructured":"Marakhouski KY, Karaseva GA, Ulasivich DN, et al. Omeprazole-domperidone fixed dose combination vs omeprazole monotherapy: a phase 4, open-label, comparative, parallel randomized controlled study in mild to moderate gastroesophageal reflux disease. Clin Med Insights. 2017;10:1179552217709456.","journal-title":"Clin Med Insights"},{"key":"753_CR28","doi-asserted-by":"crossref","unstructured":"Sigterman KE, van Pinxteren B, Bonis PA, et al (2013) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev Cd002095.","DOI":"10.1002\/14651858.CD002095.pub5"},{"key":"753_CR29","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/gutjnl-2011-301897","volume":"61","author":"D Sifrim","year":"2012","unstructured":"Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61:1340\u201354.","journal-title":"Gut"},{"key":"753_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/CEG.S121056","volume":"11","author":"J Mermelstein","year":"2018","unstructured":"Mermelstein J, Chait Mermelstein A, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol. 2018;11:119\u201334.","journal-title":"Clin Exp Gastroenterol"},{"key":"753_CR31","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.cgh.2006.09.013","volume":"4","author":"IM Gralnek","year":"2006","unstructured":"Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4:1452\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"753_CR32","unstructured":"Khan M, Santana J, Donnellan C, et al (2007) Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev Cd003244."},{"key":"753_CR33","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1007\/s10620-017-4830-5","volume":"62","author":"YM Kung","year":"2017","unstructured":"Kung YM, Hsu WH, Wu MC, et al. Recent advances in the pharmacological management of gastroesophageal reflux disease. Dig Dis Sci. 2017;62:3298\u2013316.","journal-title":"Dig Dis Sci"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-020-00753-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-020-00753-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-020-00753-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T23:05:58Z","timestamp":1623279958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-020-00753-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["753"],"URL":"https:\/\/doi.org\/10.1007\/s10388-020-00753-6","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All analyses were based on previous published studies, thus no ethical approval and patient consent are required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The authors deny any conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}